TY - JOUR
T1 - Diagnosis and management of secondary-progressive multiple sclerosis
T2 - Time for change
AU - Oh, Jiwon
AU - Alikhani, Katayoun
AU - Bruno, Tania
AU - Devonshire, Virginia
AU - Giacomini, Paul S.
AU - Giuliani, Fabrizio
AU - Nakhaipour, Hamid R.
AU - Schecter, Robyn
AU - Larochelle, Catherine
N1 - Funding Information:
J Oh discloses that she has received grants and personal fees from Biogen-Idec, Roche and Sanofi-Genzyme. She has also received personal fees from Novartis, EMD-Serono and Celgene outside the submitted work. T Bruno reports receiving honorarium from the MS Society of Canada, and EXCEMED as a speaker, research support grants from the Barford Foundation, and the Toronto Rehab Foundation. She has also received honorarium as an advisory board member for Novartis. V Devonshire reports receiving honorarium for participating in advisory board meetings and speaking engagements for EMD Serono, Biogen, Teva Neurosciences, Novartis, Sanofi-Genzyme, Roche and Allergan. PS Giacomini reports receiving honorarium from Novartis, EMD Serono, Biogen, Sanofi Genzyme, Roche, Teva for participation in advisory boards and speaking engagements, and Actelion for participating in advisory boards outside the submitted work. F Giuliani reports grants from Biogen Canada, and personal fees from Teva Neurosciences, Merck Serono, Biogen Canada, Roche and Novartis outside this submitted work. HR Nakhaipour reports that he is a former employee of Novartis Pharmaceuticals Canada. R Schecter reports that she is an employee of Novartis Pharmaceuticals Canada. C Larochelle reports receiving research grants from EMD-Serono/Merck, as well as personal fees from Sanofi-Genzyme, Celgene, Biogen, EMD-Serono, Novartis, Roche and MedDay Pharmaceuticals SA outside this submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Information:
The authors thank Jeff Alexander, SNELL Medical Communication, for editorial assistance with the preparation of this paper. Editorial assistance was funded by Novartis Pharmaceuticals Canada.
Publisher Copyright:
© 2019
PY - 2019/12
Y1 - 2019/12
N2 - Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among patients and the absence of validated biomarkers and diagnostic tools. The uncertainty associated with the transition makes clinical care challenging for both patients and physicians. The emergence of new disease-modifying treatments for progressive MS and the increasing emphasis of nonpharmacological strategies mark a new era in the treatment of progressive MS. This article summarizes challenges in diagnosis and management, discusses novel treatment strategies and highlights the importance of establishing a clear diagnosis and instituting an interdisciplinary management plan in the care of patients with progressive MS.
AB - Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among patients and the absence of validated biomarkers and diagnostic tools. The uncertainty associated with the transition makes clinical care challenging for both patients and physicians. The emergence of new disease-modifying treatments for progressive MS and the increasing emphasis of nonpharmacological strategies mark a new era in the treatment of progressive MS. This article summarizes challenges in diagnosis and management, discusses novel treatment strategies and highlights the importance of establishing a clear diagnosis and instituting an interdisciplinary management plan in the care of patients with progressive MS.
KW - biomarkers
KW - disease-modifying therapy
KW - inflammation
KW - neuroprotective
KW - secondary-progressive multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85094160589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094160589&partnerID=8YFLogxK
U2 - 10.2217/nmt-2019-0024
DO - 10.2217/nmt-2019-0024
M3 - Review article
C2 - 31769344
AN - SCOPUS:85094160589
SN - 1758-2024
VL - 9
SP - 301
EP - 317
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 6
ER -